Oxford Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Oxford Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,925	Closed	-$219K	–	468
2024 Q4	$219K	Buy	+11,925	New	+$192K	0.1%	329
2020 Q1	–	Sell	-34,476	Closed	-$1.48M	–	215
2019 Q4	$1.48M	Sell	34,476 -3,815	-10%	-$166K	0.04%	611
2019 Q3	$1.38M	Sell	38,291 -32,111	-46%	-$974K	0.03%	758
2019 Q2	$1.88M	Buy	70,402 +42,837	+155%	+$1.09M	0.04%	664
2019 Q1	$740K	Sell	27,565 -53,091	-66%	-$1.24M	0.02%	1068
2018 Q4	$1.3M	Buy	+80,656	New	+$1.57M	0.03%	711
2014 Q3	–	Sell	-25,561	Closed	-$573K	–	665
2014 Q2	$573K	Sell	25,561 -110,250	-81%	-$2.3M	0.02%	553
2014 Q1	$3.3M	Buy	+135,811	New	+$3.44M	0.1%	283

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Oxford Asset Management's ACAD Position: Q1 2025 in Review

Oxford Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 11,925 shares — an estimated $219K sold.

Oxford Asset Management first reported a position in ACAD in Q1 2014 and held it in 8 quarters. The position peaked at $3.3M in Q1 2014. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Oxford Asset Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Oxford Asset Management sold 11,925 Acadia Pharmaceuticals shares in Q1 2025, an estimated $219K.
Oxford Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Oxford Asset Management's Acadia Pharmaceuticals position peaked at $3.3M in Q1 2014.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Oxford Asset Management's 13F filing for Q1 2025, filed 15 May 2025.